Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6687MR)

This product GTTS-WQ6687MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6687MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15093MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ9880MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ6114MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ14651MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ11448MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ7535MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ15933MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ5564MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP-771
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW